NYSE:KVUE - New York Stock Exchange, Inc. - US49177J1025 - Common Stock - Currency: USD
KENVUE INC
NYSE:KVUE (1/31/2025, 12:36:04 PM)
21.615
-0.11 (-0.48%)
The current stock price of KVUE is 21.615 USD. In the past month the price increased by 2.55%. In the past year, price increased by 4.27%.
These companies lead their respective markets, making them must-haves for buy-and-hold dividend investors.
Activist investor Starboard Value LP has reportedly acquired a 7.7% stake worth approximately $500 million in Qorvo Inc. on Thursday, targeting the struggling semiconductor manufacturer for potential operational changes.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
UL | UNILEVER PLC-SPONSORED ADR | 20.79 | 142.98B | ||
HLN | HALEON PLC-ADR | 55.79 | 42.89B | ||
EL | ESTEE LAUDER COMPANIES-CL A | 32.57 | 30.75B | ||
BRBR | BELLRING BRANDS INC | 40.47 | 10.07B | ||
COTY | COTY INC-CL A | 17.73 | 6.48B | ||
ELF | ELF BEAUTY INC | 33.19 | 5.87B | ||
IPAR | INTERPARFUMS INC | 30.43 | 4.54B | ||
ODD | ODDITY TECH LTD-CL A | 24.91 | 2.73B | ||
EPC | EDGEWELL PERSONAL CARE CO | 11.02 | 1.64B | ||
OLPX | OLAPLEX HOLDINGS INC | 12.15 | 1.05B | ||
HNST | HONEST CO INC/THE | N/A | 653.21M | ||
USNA | USANA HEALTH SCIENCES INC | 12 | 647.47M |
Kenvue, Inc. is a consumer health company. The company is headquartered in Skillman, New Jersey and currently employs 21,780 full-time employees. The company went IPO on 2023-05-04. The firm operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. Its Self Care product categories include Pain Care; Cough, Cold, and Allergy; and Other Self Care (Digestive Health; Smoking Cessation; Eye Care; and Other). The Skin Health and Beauty segment's product categories include face and body care and hair, sun, and others. The Essential Health segment's product categories include oral care, baby care and other essential health (women’s health, wound care, and other). Its differentiated portfolio of brands includes Tylenol, Neutrogena, Listerine, Johnson’s, Band-Aid, Aveeno, Zyrtec, and Nicorette. The firm has a global footprint through which it sells and distributes its product portfolio in more than 165 countries across its four regions. The four region consists of North America, Asia Pacific (APAC), Europe, Middle East, and Africa (EMEA), and Latin America (LATAM).
KENVUE INC
199 Grandview Road
Skillman NEW JERSEY US
Employees: 21780
Company Website: https://www.kenvue.com
Investor Relations: https://investors.kenvue.com/overview/default.aspx
Phone: 17325240400
The current stock price of KVUE is 21.615 USD.
The exchange symbol of KENVUE INC is KVUE and it is listed on the New York Stock Exchange, Inc. exchange.
KVUE stock is listed on the New York Stock Exchange, Inc. exchange.
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for KVUE, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of KVUE.
KVUE has a dividend yield of 3.95%. The yearly dividend amount is currently 0.
KVUE will report earnings on 2025-02-06, before the market open.
The PE ratio for KVUE is 18.16. This is based on the reported non-GAAP earnings per share of 1.19 and the current share price of 21.615 USD.
The outstanding short interest for KVUE is 1.86% of its float.
ChartMill assigns a technical rating of 2 / 10 to KVUE. When comparing the yearly performance of all stocks, KVUE is a bad performer in the overall market: 63.27% of all stocks are doing better.
ChartMill assigns a fundamental rating of 4 / 10 to KVUE. KVUE has a medium profitability rating, but doesn't score so well on its financial health evaluation.
Over the last trailing twelve months KVUE reported a non-GAAP Earnings per Share(EPS) of 1.19. The EPS increased by -41.49% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | 6.88% | ||
ROA | 3.95% | ||
ROE | 10% | ||
Debt/Equity | 0.75 |
ChartMill assigns a Buy % Consensus number of 72% to KVUE. The Buy consensus is the average rating of analysts ratings from 23 analysts.
For the next year, analysts expect an EPS growth of -11.15% and a revenue growth 0.07% for KVUE